Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
CEO Brett Monia Took The Helm At Start Of Transition
Executive Summary
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.
You may also be interested in...
AstraZeneca/Ionis’s Eplontersen Shows Competitive Efficacy In ATTR Polyneuropathy At 66 Weeks
Patients continued to improve across all three Phase III NEURO-TTRansform co-primary endpoints with 29 more weeks of treatment, setting up eplontersen to challenge Alnylam’s Amvuttra.
Biogen Drug Sends Tau Into Reverse: An Alzheimer’s Breakthrough In The Making?
Phase I study and open-label extension results show a big drop in tau levels, which are more closely linked to Alzheimer’s symptoms than amyloid beta – setting up hopes of success in an ongoing Phase II study.
Ionis Enters $500m+ Agreement With Royalty Pharma To Help Fund Late-Stage Pipeline
The US firm has sold some of its royalty stream for the gene therapy Spinraza and cardiovascular drug candidate, pelacarsen, to Royalty Pharma for $500m upfront, which should help fund upcoming milestones for Ionis’ late-stage pipeline.